259 results were returned
The French so-called “anti-gift” provisions strictly frame the conditions under which companies in the health sector are allowed to provide advantages, in cash or in kind, to healthcare professionals ("HCPs”)
The Supreme Court has confirmed that a patent for a dosage regime of a drug used to treat erectile dysfunction (ED) was obvious over the prior art.
New CNIL standard for all companies doing product vigilance activities
On 1 August 2019, the National Medical Products Administration ("NMPA") issued a notice to extend the pilot project of medical device registrant system (GUO YAO JIAN XIE ZHU (2019) No.33) ("Notice") to 21 ...
The Patents Court has considered enablement in relation to anticipation of a claimed monoclonal antibody invention by prior art, and held the patent was invalid for lack of novelty; it was also obvious for lack of ...
On 26 August 2019, China's National People's Congress passed the final amendments to the Drug Administration Law ("DAL"), which will take effect on 1 December 2019. The DAL was first enacted in 1984, then substantively ...
The Bill of the Law on the organization and transformation of the French healthcare system at the French parliament, adoption of the final version is expected for the end of July.
Biotech and medtech companies operate in an international environment where the composition of their governance bodies is a key criterion of credibility.
The French Health Data Hub was born officially with the publication on 30 November 2019 of a ministerial decision (arrêté).
Before the entry into force of the GDPR on May 25th 2018, healthcare professionals and facilities and professionals in medico-social sectors empowered by law in France had to comply with the provisions stated in the ...